Xencor, Inc. (XNCR)
Largest Insider Buys in Sector
XNCR Stock Price History Chart
XNCR Stock Performance
About Xencor, Inc.
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
Insider Activity of Xencor, Inc.
Over the last 12 months, insiders at Xencor, Inc. have bought $1,013 and sold $3.21M worth of Xencor, Inc. stock.
On average, over the past 5 years, insiders at Xencor, Inc. have bought $1,013 and sold $11.88M worth of stock each year.
Highest buying activity among insiders over the last 12 months: GORMAN KEVIN CHARLES (director) — $2,027.
The last purchase of 53 shares for transaction amount of $1,013 was made by GORMAN KEVIN CHARLES (director) on 2024‑02‑13.
List of Insider Buy and Sell Transactions, Xencor, Inc.
| 2024-05-02 | Sale | Valente Nancy | EVP, Chief Development Officer | 4,745 0.0077% | $23.58 | $111,872 | -4.11% | |
| 2024-03-11 | Sale | Dahiyat Bassil I | PRESIDENT & CEO | 2,741 0.0046% | $23.50 | $64,418 | -5.40% | |
| 2024-03-11 | Sale | Desjarlais John R | SR. VICE PRESIDENT & CSO | 1,280 0.0021% | $23.50 | $30,082 | -5.40% | |
| 2024-03-11 | Sale | Kuch John J | SR. VICE PRESIDENT & CFO | 849 0.0014% | $23.50 | $19,953 | -5.40% | |
| 2024-03-11 | Sale | Eckert Celia | SVP, GENERAL COUNSEL | 850 0.0014% | $23.50 | $19,977 | -5.40% | |
| 2024-03-06 | Sale | GUSTAFSON KURT A | director | 14,000 0.0222% | $23.18 | $324,453 | -7.93% | |
| 2024-03-05 | Sale | Dahiyat Bassil I | PRESIDENT & CEO | 12,528 0.0209% | $23.43 | $293,519 | -3.98% | |
| 2024-03-05 | Sale | Desjarlais John R | SR. VICE PRESIDENT & CSO | 6,629 0.011% | $23.43 | $155,311 | -3.98% | |
| 2024-03-05 | Sale | Kuch John J | SR. VICE PRESIDENT & CFO | 4,474 0.0075% | $23.43 | $104,821 | -3.98% | |
| 2024-03-05 | Sale | Eckert Celia | SVP, GENERAL COUNSEL | 3,892 0.0065% | $23.43 | $91,186 | -3.98% | |
| 2024-02-13 | Sale | Desjarlais John R | SR. VICE PRESIDENT & CSO | 54,108 0.084% | $19.38 | $1.05M | +17.26% | |
| 2024-02-13 | GORMAN KEVIN CHARLES | director | 53 <0.0001% | $19.12 | $1,013 | +17.26% | ||
| 2023-12-29 | Sale | Dahiyat Bassil I | PRESIDENT & CEO | 45,000 0.073% | $20.93 | $941,670 | +1.84% | |
| 2023-06-21 | Sale | Dahiyat Bassil I | PRESIDENT & CEO | 33,497 0.0568% | $26.19 | $877,286 | -17.57% | |
| 2023-03-09 | Sale | Dahiyat Bassil I | PRESIDENT & CEO | 2,602 0.0044% | $29.88 | $77,746 | -22.82% | |
| 2023-03-09 | Sale | Desjarlais John R | SR. VICE PRESIDENT & CSO | 1,230 0.0021% | $29.88 | $36,752 | -22.82% | |
| 2023-03-09 | Sale | Kuch John J | SR. VICE PRESIDENT & CFO | 711 0.0012% | $29.88 | $21,244 | -22.82% | |
| 2023-03-09 | Sale | Yang Allen | SR. VICE PRESIDENT & CMO | 1,094 0.0019% | $29.88 | $32,688 | -22.82% | |
| 2023-03-09 | Sale | Eckert Celia | VP, GENERAL COUNSEL | 711 0.0012% | $29.88 | $21,244 | -22.82% | |
| 2023-03-06 | Sale | Dahiyat Bassil I | PRESIDENT & CEO | 5,831 0.0096% | $31.42 | $183,186 | -28.63% |
Insider Historical Profitability
| Dahiyat Bassil I | PRESIDENT & CEO | 351894 0.5141% | $19.43 | 0 | 15 | |
| Desjarlais John R | SR. VICE PRESIDENT & CSO | 186433 0.2427% | $19.43 | 0 | 19 | |
| Kuch John J | SR. VICE PRESIDENT & CFO | 121070 0.2074% | $19.43 | 0 | 15 | |
| Valente Nancy | EVP, Chief Development Officer | 55115 0.0894% | $19.43 | 0 | 1 | |
| Eckert Celia | VP, GENERAL COUNSEL | 45465 0.0607% | $19.43 | 0 | 8 | |
| GUSTAFSON KURT A | director | 6007 0.0098% | $19.43 | 0 | 1 | |
| GORMAN KEVIN CHARLES | director | 5060 0.0083% | $19.43 | 1 | 0 | |
| Ronin Capital, LLC | 10 percent owner | 5012430 8.2339% | $19.43 | 0 | 2 | |
| STAFFORD JOHN S JR | 10 percent owner | 2000443 3.2861% | $19.43 | 1 | 0 | +31.06% |
| STAFFORD JOHN S III | 10 percent owner | 606005 0.9955% | $19.43 | 33 | 42 | +42.66% |
| Yang Allen | SR. VICE PRESIDENT & CMO | 73364 0.1205% | $19.43 | 0 | 6 | |
| CARTER BRUCE L A | director | 48578 0.0798% | $19.43 | 0 | 5 | |
| Foster Paul A | Chief Medical Officer | 4952 0.0081% | $19.43 | 0 | 9 | |
| Baracchini Edgardo Jr | Chief Business Officer | 207 0.0003% | $19.43 | 0 | 30 |
Institutional Investor Ownership
| BlackRock | $244.64M | 17.93 | 11.05M | -2.37% | -$5.95M | 0.01 | |
| PRIMECAP Management Co | $201.18M | 14.74 | 9.09M | +2.12% | +$4.18M | 0.15 | |
| The Vanguard Group | $155.15M | 11.37 | 7.01M | +3.6% | +$5.4M | <0.01 | |
| Ecor1 Capital Llc | $117.96M | 8.64 | 5.33M | +0.91% | +$1.06M | 3 | |
| State Street | $93.73M | 6.87 | 4.24M | +27.31% | +$20.11M | <0.01 | |
| T. Rowe Price | $84.53M | 6.19 | 3.82M | +9.64% | +$7.43M | 0.01 | |
| Dimensional Fund Advisors | $30.35M | 2.22 | 1.37M | +7.22% | +$2.04M | 0.01 | |
| Geode Capital Management | $29.88M | 2.19 | 1.35M | +2.65% | +$771,194.87 | <0.01 | |
| Darwin Global Management Ltd | $24.56M | 1.8 | 1.11M | New | +$24.56M | 3.65 | |
| Armistice Capital Llc | $22.13M | 1.62 | 1M | -33.33% | -$11.06M | 0.26 | |
| Loomis, Sayles & Company | $21.2M | 1.55 | 957,811 | -3.08% | -$673,470.93 | 0.03 | |
| Point72 Asset Management | $18.27M | 1.34 | 825,400 | New | +$18.27M | 0.04 | |
| Millennium Management LLC | $18.21M | 1.34 | 822,976 | +134.99% | +$10.46M | 0.01 | |
| Morgan Stanley | $17.76M | 1.3 | 802,689 | +7.74% | +$1.28M | <0.01 | |
| Johnson & Johnson | $16.55M | 1.21 | 748,062 | 0% | +$0 | 0.38 | |
| Northern Trust | $15.14M | 1.11 | 684,284 | -4.82% | -$766,472.55 | <0.01 | |
| Candriam S C A | $14.41M | 1.06 | 651,317 | -8% | -$1.25M | 0.09 | |
| Logos Global Management Lp | $14.38M | 1.05 | 650,000 | New | +$14.38M | 1.54 | |
| Two Sigma Advisers LP | $13.32M | 0.98 | 601,900 | +88.56% | +$6.26M | 0.02 | |
| Two Sigma | $13.27M | 0.97 | 599,513 | +51.5% | +$4.51M | 0.02 | |
| Charles Schwab | $12.24M | 0.9 | 552,922 | +6.19% | +$713,117.13 | <0.01 | |
| Baker Bros Advisors LP | $12.07M | 0.89 | 545,431 | +122.23% | +$6.64M | 0.15 | |
| Bank of America | $10.92M | 0.8 | 493,315 | +313.26% | +$8.28M | <0.01 | |
| BNY Mellon | $10.73M | 0.79 | 484,734 | -4.74% | -$533,709.14 | <0.01 | |
| Goldman Sachs | $7.49M | 0.55 | 338,508 | -22.7% | -$2.2M | <0.01 | |
| Citadel Advisors LLC | $7.04M | 0.52 | 318,100 | +87.7% | +$3.29M | 0.01 | |
| Ubs Asset Management Americas Inc | $5.97M | 0.44 | 269,693 | +0.13% | +$7,767.63 | <0.01 | |
| Ameriprise Financial | $5.09M | 0.37 | 229,876 | -9.62% | -$541,609.63 | <0.01 | |
| Citigroup | $5.07M | 0.37 | 229,111 | +178.87% | +$3.25M | <0.01 | |
| Rafferty Asset Management Llc | $5.08M | 0.37 | 229,371 | +91.43% | +$2.42M | 0.02 | |
| Russell Investments Group Ltd | $4.96M | 0.36 | 224,140 | +43.11% | +$1.49M | 0.01 | |
| RHENMAN & PARTNERS ASSET MANAGEMENT AB | $4.84M | 0.36 | 218,750 | -2.78% | -$138,312.51 | 0.46 | |
| Panagora | $4.7M | 0.34 | 212,332 | -2.73% | -$131,806.28 | 0.02 | |
| UBS | $4.67M | 0.34 | 210,805 | +10,440.25% | +$4.62M | <0.01 | |
| Hudson Bay Capital Management LP | $4.64M | 0.34 | 209,800 | -14.37% | -$778,976.00 | 0.05 | |
| Dcf Advisers Llc | $4.62M | 0.34 | 208,979 | -11.86% | -$622,472.60 | 2.85 | |
| Jacobs Levy Equity Management | $4.61M | 0.34 | 208,227 | New | +$4.61M | 0.02 | |
| Invesco | $4.49M | 0.33 | 202,955 | -10.77% | -$542,096.46 | <0.01 | |
| Macquarie Group | $4.43M | 0.32 | 200,000 | +54.81% | +$1.57M | <0.01 | |
| Franklin Templeton Investments | $4.35M | 0.32 | 196,452 | New | +$4.35M | <0.01 | |
| Schonfeld Group | $4.29M | 0.32 | 193,972 | +16.77% | +$616,563.73 | 0.03 | |
| Cubist Systematic Strategies | $4.28M | 0.31 | 193,344 | +41.03% | +$1.24M | 0.04 | |
| Legal & General | $4.17M | 0.31 | 188,383 | +10.8% | +$406,350.98 | <0.01 | |
| Standard Life | $3.88M | 0.29 | 175,520 | 0% | +$0 | 0.01 | |
| ExodusPoint Capital Management, LP | $3.85M | 0.28 | 173,969 | -38.05% | -$2.36M | 0.05 | |
| Nuveen | $3.35M | 0.25 | 151,525 | -8.89% | -$327,280.55 | <0.01 | |
| RhumbLine Advisers | $3.33M | 0.24 | 150,308 | -18.68% | -$763,988.01 | <0.01 | |
| Silvercrest Asset Management Group Inc | $3.19M | 0.23 | 144,235 | +4.56% | +$139,286.24 | 0.02 | |
| Td Asset Management Inc | $3.17M | 0.23 | 143,450 | +16.39% | +$447,026.07 | <0.01 | |
| JPMorgan Chase | $2.86M | 0.21 | 129,211 | -74.22% | -$8.23M | <0.0001 |